• Braeburn achieves endpoints in implant study to treat Schizophrenia europeanpharmaceuticalreview
    May 08, 2017
    Braeburn Pharmaceuticals’ 6-month study of the safety, tolerability and pharmacokinetics of transferring patients diagnosed with schizophrenia or schizoaffective disorder and stabilized on oral risperidone to BB0817 (risperidone) implant has met its prima
PharmaSources Customer Service